Kiniksa Pharmaceuticals LtdNASDAQ:KNSA
- LAST PRICE18.1200
- TODAY'S CHANGE (%)0.4400 (2.4887%)
- Bid / Lots18.1100/ 4
- Ask / Lots18.1700/ 1
- Open / Previous Close18.2100 / 17.6800
- Day Range
- 52 Week Range
- Volume91,225
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KNSA |
|---|---|---|
| 09:32 ET | 17366 | 17.96 |
| 09:36 ET | 1620 | 18.21 |
| 09:38 ET | 826 | 18.155 |
| 09:39 ET | 400 | 18.15 |
| 09:41 ET | 1382 | 18.09 |
| 09:43 ET | 1036 | 18.12 |
| 09:45 ET | 1144 | 18.15 |
| 09:48 ET | 900 | 18.21 |
| 09:50 ET | 2815 | 18.28 |
| 09:52 ET | 800 | 18.32 |
| 09:54 ET | 1838 | 18.4 |
| 09:56 ET | 1300 | 18.41 |
| 09:57 ET | 200 | 18.44 |
| 09:59 ET | 3142 | 18.34 |
| 10:01 ET | 1122 | 18.28 |
| 10:03 ET | 3543 | 18.28 |
| 10:06 ET | 100 | 18.28 |
| 10:08 ET | 1400 | 18.425 |
| 10:10 ET | 1400 | 18.41 |
| 10:14 ET | 600 | 18.5 |
| 10:15 ET | 200 | 18.445 |
| 10:17 ET | 827 | 18.45 |
| 10:19 ET | 300 | 18.46 |
| 10:24 ET | 400 | 18.43 |
| 10:26 ET | 358 | 18.405 |
| 10:28 ET | 7528 | 18.54 |
| 10:30 ET | 127 | 18.59 |
| 10:32 ET | 508 | 18.571 |
| 10:33 ET | 1700 | 18.49 |
| 10:37 ET | 1090 | 18.41 |
| 10:39 ET | 200 | 18.37 |
| 10:42 ET | 600 | 18.32 |
| 10:44 ET | 100 | 18.34 |
| 10:46 ET | 1364 | 18.25 |
| 10:48 ET | 400 | 18.25 |
| 10:50 ET | 755 | 18.2 |
| 10:51 ET | 400 | 18.165 |
| 10:53 ET | 2281 | 18.1499 |
| 10:57 ET | 900 | 18.07 |
| 11:00 ET | 300 | 18.025 |
| 11:02 ET | 700 | 18 |
| 11:04 ET | 1400 | 17.985 |
| 11:06 ET | 3750 | 18.02 |
| 11:08 ET | 600 | 18.09 |
| 11:09 ET | 486 | 18.08 |
| 11:11 ET | 506 | 18.12 |
Yesterday
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution, from 7:30AM ET on Tuesday Apr 23, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 23, 2024 by Dow Jones*DJ Kiniksa Pharmaceuticals 1Q Loss/Shr 25c >KNSA, from 7:30AM ET on Tuesday Apr 23, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 16, 2024
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024, from 4:01PM ET on Tuesday Apr 16, 2024 by Dow Jones
4:01PM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 2, 2024
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart, from 7:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
7:30AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.2B | 212.7x | --- |
Zai Lab Ltd | 1.5B | -4.6x | --- |
ADMA Biologics Inc | 1.5B | -51.3x | --- |
Dynavax Technologies Corp | 1.5B | -157.1x | --- |
MannKind Corp | 1.1B | -91.8x | --- |
Mirum Pharmaceuticals Inc | 1.1B | -5.9x | --- |
Company Information
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Contact Information
- Headquarters
- Clarendon House, 2 Church StreetHAMILTON, Bermuda HM11
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Sanjiv Patel
- Chief Financial Officer, Senior Vice President
- Mark Ragosa
- Chief Operating Officer, Senior Vice President
- Eben Tessari
- Senior Vice President and Chief Commercial Officer
- Ross Moat
- Senior Vice President and Chief Medical Officer
- John Paolini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
|---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 212.7x |
Price/Sales (TTM) | 4.1 |
Price/Cash Flow (TTM) | 44.4x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
